VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vaxart, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026
- Market cap
- $115.15M
- P/E (TTM)
- 3.2
- Dividend yield
- –
Vaxart statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Vaxart | Industry median |
|---|---|---|
| Market Cap | $115.47M | $166.30M |
| Enterprise Value | $51.47M | $88.19M |
| PE Ratio | 3.17 | 20.44 |
| PS Ratio | 0.48 | 3.65 |
| PB Ratio | 1.40 | 2.03 |
| P/TBV Ratio | 1.53 | 2.29 |
| P/FCF Ratio | 3.46 | 17.44 |
| P/OCF Ratio | 3.40 | 12.98 |
Enterprise value
| Measure | Vaxart | Industry median |
|---|---|---|
| EV / Sales | 0.21 | 2.51 |
| EV / EBITDA | 1.13 | 14.65 |
| EV / EBIT | 1.30 | 19.00 |
| EV / FCF | 1.54 | 20.86 |
Income (trailing twelve months)
| Measure | Vaxart | Industry median |
|---|---|---|
| Revenue | $243.06M | $58.34M |
| Operating Income | $39.61M | -$21.40M |
| Pretax Income | $39.01M | -$14.34M |
| Net Income | $38.59M | -$22.46M |
| EBITDA | $45.62M | -$16.91M |
| EPS (Diluted) | $0.15 | -$0.83 |
Margins
| Measure | Vaxart | Industry median |
|---|---|---|
| Operating Margin | 16.3% | -44.0% |
| Pretax Margin | 16.0% | -13.3% |
| Profit Margin | 15.9% | -40.2% |
| EBITDA Margin | 18.8% | -30.2% |
| FCF Margin | 13.7% | -9.27% |
Returns
| Measure | Vaxart | Industry median |
|---|---|---|
| Return on Equity (ROE) | 67.0% | -53.2% |
| Return on Assets (ROA) | 23.4% | -40.9% |
| Return on Invested Capital (ROIC) | 314.1% | -32.4% |
| Return on Capital Employed (ROCE) | 43.0% | -38.1% |
Growth
| Measure | Vaxart | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 201.1% | 5.96% |
| Revenue Growth (3Y CAGR) | 1204.0% | 2.25% |
| Revenue Growth (5Y CAGR) | 125.8% | 6.48% |
Balance sheet
| Measure | Vaxart | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $64.00M | $61.43M |
| Net Cash (Debt) | $64.00M | $15.35M |
| Net Cash Per Share | $0.26 | $0.66 |
| Equity (Book Value) | $82.37M | $49.09M |
| Book Value Per Share | $0.34 | $1.37 |
| Tangible Book Value | $75.40M | $23.52M |
| Working Capital | $43.58M | $76.81M |
Financial position
| Measure | Vaxart | Industry median |
|---|---|---|
| Current Ratio | 1.60 | 3.34 |
| Quick Ratio | 0.88 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Vaxart | Industry median |
|---|---|---|
| Operating Cash Flow | $33.98M | -$12.35M |
| Capital Expenditures | -$601.00K | -$1.08M |
| Free Cash Flow | $33.38M | -$20.22M |
| FCF Per Share | $0.14 | -$0.42 |
Efficiency
| Measure | Vaxart | Industry median |
|---|---|---|
| Asset Turnover | 1.48 | 0.39 |
| Revenue Per Employee | $3.74M | $404.87K |
| Profits Per Employee | $593.68K | -$703.34K |
| Employee Count | 65 | 74 |
Dividends and yields
| Measure | Vaxart | Industry median |
|---|---|---|
| Earnings Yield | 33.4% | -23.3% |
| FCF Yield | 28.9% | -8.72% |
Shares
| Measure | Vaxart | Industry median |
|---|---|---|
| Shares Outstanding | 242,835,000 | 58,127,000 |
| Shares Change (YoY) | 4.15% | 10.9% |
| Shares Change (QoQ) | 0.59% | 0.54% |
| Float | 235,020,000 | 49,136,700 |
| Shares Held by Insiders | 3.22% | 11.6% |
| Shares Held by Institutions | 0.03% | 59.4% |
Taxes
| Measure | Vaxart | Industry median |
|---|---|---|
| Income Tax | $419.00K | $79.87K |
| Effective Tax Rate | 1.07% | 20.6% |
Scores
| Measure | Vaxart | Industry median |
|---|---|---|
| Graham Number | $1.07 | $18.73 |
| Graham Upside | 125.0% | -45.1% |
| Altman Z-Score | -0.55 | -0.22 |
| Piotroski F-Score | 6 | 4 |
Calculated by StockData from Vaxart's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.